337 related articles for article (PubMed ID: 23495824)
41. Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease.
Pous-Serrano S; Frasson M; Cerrillo E; Beltrán B; Iborra M; Hervás D; García-Granero E; Nos P
J Surg Res; 2017 Jun; 213():290-297. PubMed ID: 28601328
[TBL] [Abstract][Full Text] [Related]
42. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.
Eder P; Stawczyk-Eder K; Łykowska-Szuber L; Krela-Kaźmierczak I; Klimczak K; Szymczak A; Szachta P; Linke K
Pol Arch Med Wewn; 2014; 124(1-2):51-7. PubMed ID: 24424551
[TBL] [Abstract][Full Text] [Related]
43. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
44. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease.
Shaoul R; Sladek M; Turner D; Paeregaard A; Veres G; Wauters GV; Escher J; Dias JA; Lionetti P; Staino A; Kolho KL; de Ridder L; Nuti F; Cucchiara S; Sheva O; Levine A;
Inflamm Bowel Dis; 2012 Aug; 18(8):1493-7. PubMed ID: 22275268
[TBL] [Abstract][Full Text] [Related]
45. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.
Sipponen T; Kärkkäinen P; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Aliment Pharmacol Ther; 2008 Nov; 28(10):1221-9. PubMed ID: 18752630
[TBL] [Abstract][Full Text] [Related]
46. Aberrant Motility in Unaffected Small Bowel is Linked to Inflammatory Burden and Patient Symptoms in Crohn's Disease.
Menys A; Makanyanga J; Plumb A; Bhatnagar G; Atkinson D; Emmanuel A; Taylor SA
Inflamm Bowel Dis; 2016 Feb; 22(2):424-32. PubMed ID: 26509756
[TBL] [Abstract][Full Text] [Related]
47. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy.
Koulaouzidis A; Douglas S; Rogers MA; Arnott ID; Plevris JN
Scand J Gastroenterol; 2011 May; 46(5):561-6. PubMed ID: 21269246
[TBL] [Abstract][Full Text] [Related]
48. Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn's disease.
Yang L; Ge ZZ; Gao YJ; Li XB; Dai J; Zhang Y; Xue HB; Zhao YJ
J Gastroenterol Hepatol; 2013 May; 28(5):829-33. PubMed ID: 23425203
[TBL] [Abstract][Full Text] [Related]
49. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.
van Rheenen PF
Inflamm Bowel Dis; 2012 Nov; 18(11):2018-25. PubMed ID: 22275341
[TBL] [Abstract][Full Text] [Related]
50. Diffusion-weighted imaging for evaluating inflammatory activity in Crohn's disease: comparison with histopathology, conventional MRI activity scores, and faecal calprotectin.
Pendsé DA; Makanyanga JC; Plumb AA; Bhatnagar G; Atkinson D; Rodriguez-Justo M; Halligan S; Taylor SA
Abdom Radiol (NY); 2017 Jan; 42(1):115-123. PubMed ID: 27567607
[TBL] [Abstract][Full Text] [Related]
51. Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines.
Bourgonje AR; von Martels JZH; de Vos P; Faber KN; Dijkstra G
PLoS One; 2018; 13(2):e0193202. PubMed ID: 29466406
[TBL] [Abstract][Full Text] [Related]
52. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon.
Jensen MD; Kjeldsen J; Nathan T
Scand J Gastroenterol; 2011 Jun; 46(6):694-700. PubMed ID: 21456899
[TBL] [Abstract][Full Text] [Related]
53. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
54. [Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests].
Malícková K; Janatková I; Bortlík M; Komárek V; Lukás M
Epidemiol Mikrobiol Imunol; 2008 Nov; 57(4):147-53. PubMed ID: 19069028
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology.
Dolwani S; Metzner M; Wassell JJ; Yong A; Hawthorne AB
Aliment Pharmacol Ther; 2004 Sep; 20(6):615-21. PubMed ID: 15352909
[TBL] [Abstract][Full Text] [Related]
56. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Renzulli P; Seibold F
Inflamm Bowel Dis; 2009 Dec; 15(12):1851-8. PubMed ID: 19462421
[TBL] [Abstract][Full Text] [Related]
57. The diagnostic accuracy of faecal calprotectin and small bowel capsule endoscopy and their correlation in suspected isolated small bowel Crohn's disease.
Hale MF; Drew K; McAlindon ME; Sidhu R
Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1145-50. PubMed ID: 27384306
[TBL] [Abstract][Full Text] [Related]
58. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease.
Erichsen K; Ulvik RJ; Nysaeter G; Johansen J; Ostborg J; Berstad A; Berge RK; Hausken T
Scand J Gastroenterol; 2005 Sep; 40(9):1058-65. PubMed ID: 16165718
[TBL] [Abstract][Full Text] [Related]
59. Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease.
Shentova R; Baycheva M; Kofinova D; Hadjiiski P; Yaneva P
Folia Med (Plovdiv); 2020 Jun; 62(2):271-275. PubMed ID: 32666743
[TBL] [Abstract][Full Text] [Related]
60. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
